Company / SG&A Expense
AVADEL PHARMACEUTICALS PLC SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$181.0M
FY2024
5-year range
$32.4M / $181.0M
FY2020-FY2024
Trend
+19.3%
vs FY2023
Sector context
#77 of 213
Health Care
What the data says
At $181M, AVADEL PHARMACEUTICALS PLC's sg&a expense ranks #137 of 213 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $30M in FY2019 to $181M in FY2024.
Based on SEC 10-K filings.
$181M in FY2024 with a 5-year CAGR of +43.1%.
Increased from $75M to $181M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +38.3%
- 5-Year CAGR
- +43.1%
- 10-Year CAGR
- -
Sector benchmark
#137 of 213 in Health CareTop 64% of 213This company $181.0M Sector average $722.3M
▼
-74.9% below sector average
Key checks
Key Insights
- AVADEL PHARMACEUTICALS PLC's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +43.1%, indicating consistent growth.
- In FY2024, sg&a expense increased 19.3% year-over-year.
- Ranks #77 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $181.0M | +19.3% |
| FY2023 | $151.7M | +103.6% |
| FY2022 | $74.5M | +8.8% |
| FY2021 | $68.5M | +111.4% |
| FY2020 | $32.4M | +7.4% |
| FY2019 | $30.2M | -69.9% |
| FY2018 | $100.4M | +70.5% |
| FY2017 | $58.9M | +33.2% |
| FY2016 | $44.2M | +103.5% |
| FY2015 | $21.7M | +38.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026